A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson, Tom De Soyza, Anthony Carroll, Miles Chalmers, James D Crooks, Michael G Griffiths, Gareth Shankar-Hari, Manu Ho, Ling-Pei Horsley, Alex Kell, Chris
Wilkinson, Tom
De Soyza, Anthony
Carroll, Miles
Chalmers, James D
Crooks, Michael G
Griffiths, Gareth
Shankar-Hari, Manu
Ho, Ling-Pei
Horsley, Alex
Kell, Chris
Abstract
Efficacy analyses included 97 patients (tozorakimab+SoC, n=53; SoC, n=44). Median time to clinical response did not differ between the tozorakimab and SoC arms (8.0 and 9.5 days, respectively; HR 0.96, 80% CI 0.70-1.31; one-sided p=0.33). Tozorakimab was well tolerated and the OR for risk of death or respiratory failure with treatment versus SoC was 0.55 (80% CI 0.27-1.12; p=0.26), while the OR was 0.31 (80% CI 0.09-1.06) in patents with high baseline serum IL-33/sST2 complex levels.
MIDER Authors
Citations
Altmetric:
Date
2023-10-02
Type
Article
Subject
Respiratory medicine
Collections
Citation
ERJ Open Res . 2023 Oct 2;9(5):00249-2023
Journal / Source Title
ERJ Open Research
DOI
10.1183/23120541.00249-2023
PMID
37868151
Publisher
European Respiratory Society
Publisher’s URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588785/